Cancer Stem Cell News Volume 10.09 | Mar 10 2021


    2021-03-10 | CSCN 10.09

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.09 – 10 March, 2021

    ESE3/EHF, a Promising Target of Rosiglitazone, Suppresses Pancreatic Cancer Stemness by Downregulating CXCR4

    The authors identified E26 transformation-specific homologous factor as a key molecule in decreasing the sensitivity of pancreatic cancer cells to cancer stem cells’ niche stimulus.

    Enter a contest to win a personalized lab coat by subscribing to Organoid News!
    PUBLICATIONSRanked by the impact factor of the journal

    RALYL Increases Hepatocellular Carcinoma Stemness by Sustaining the mRNA Stability of TGF-β2

    Human embryonic stem cells were induced to differentiate into hepatocytes along hepatic lineages to mimic liver development in vitro.
    [Nature Communications]

    Full Article

    Phosphorylation State of the Histone Variant H2A.X Controls Human Stem and Progenitor Cell Fate Decisions

    Investigators revealed that the phosphorylation state of the HV H2A.X (γH2A.X) regulated self-renewal and differentiation of human pluripotent stem cells and leukemic progenitors.
    [Cell Reports]

    Full ArticleGraphical Abstract

    YAP1 Overexpression Contributes to the Development of Enzalutamide Resistance by Induction of Cancer Stemness and Lipid Metabolism in Prostate Cancer

    Innovated AR-independent therapy might alleviate enzalutamide resistance and prevent production of adverse side effects. Scientists identified that yes-associated protein 1 (YAP1) was overexpressed in enzalutamide-resistant cells.

    Full Article

    Aurora-A Kinase Oncogenic Signaling Mediates TGF-β-Induced Triple-Negative Breast Cancer Plasticity and Chemoresistance

    Researchers demonstrated that aurora-A kinase is required to mediate TGF-β-induced expression of the SNAI1 gene, enrichment of ALDH1high breast tumor-initiating cells, self-renewal capacity, and chemoresistance in TNBC experimental models.

    Full Article

    GASC1 Promotes Hepatocellular Carcinoma Progression by Inhibiting the Degradation of ROCK2

    A distinct heterogeneity in GASC1 levels was observed among hepatocellular carcinoma cell populations, predicting their inherent high or low tumor-initiating capacity.
    [Cell Death & Disease]

    Full Article

    Identification and Characterization of a Subpopulation of CD133+ Cancer Stem-Like Cells Derived from SK-UT-1 Cells

    Scientists characterized and identify a subpopulation of CD133+ cancer stem-like cells derived from SK-UT-1 cell line.
    [Cancer Cell International]

    Full Article

    Conditionally Immortalized Leukemia Initiating Cells Co-Expressing Hoxa9/Meis1 Demonstrate Microenvironmental Adaptation Properties Ex Vivo while Maintaining Myelomonocytic Memory

    Investigators established conditionally immortalised myeloid progenitor cell lines co-expressing constitutive Hoxa9.EGFP and inducible Meis1.dTomato to study growth behavior, immunophenotype and morphology under different cytokine/microenvironmental conditions ex vivo upon doxycycline induction or removal.
    [Scientific Reports]

    Full Article

    Acquisition of Cancer Stem Cell Capacities after Spontaneous Cell Fusion

    CSC capacities were evaluated regarding capacity to form spheres, expression of stem cell markers and the presence of ALDHhigh cells.
    [BMC Cancer]

    Full Article
    Free E-Book: Genome Editing Applications for Disease Modeling and Cell Therapy.

    Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors

    Scientists discuss the metabolic properties of leukemia stem cells and how targeting energy metabolism may provide more effective therapeutic regimens for leukemia patients.
    [Cell Stem Cell]


    The Key Roles of Cancer Stem Cell-Derived Extracellular Vesicles

    Investigators summarize the molecular mechanism by which CSCs-derived extracellular vesicles in tumor progression.
    [Signal Transduction and Targeted Therapy]

    Full Article

    A Review of Circulating Tumour Cell Enrichment Technologies

    The authors review a wide range of both immunocapture and label free circulating tumor cell enrichment technologies, summarising the most significant advantages and disadvantages of each.

    Full Article

    OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma

    OncoSynergy, Inc. announced that the first patient was treated in the company’s First-in-Human Phase I clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 therapeutic to reach human trials.
    [OncoSynergy, Inc. (PR Newswire. LLC)]

    Press Release

    US FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

    Kite, a Gilead Company announced that the FDA has granted accelerated approval to Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
    [Gilead Sciences, Inc.]

    Press Release

    Norcross Announces More Than $408K for Cancer Research at Coriell Institute

    US Congressman Donald Norcross announced that the Coriell Institute for Medical Research, located in Camden, has been awarded a $408,617 grant from the National Cancer Institute. This grant will go towards a research project aimed at exploring drug resistance in patients with acute myeloid leukemia.
    [Donald Norcross]

    Press Release

    Tumor Heterogeneity, Plasticity and Therapy

    May 5 – 6, 2021

    > See All Events


    Postdoctoral Fellow Position – Sarcoma Biology

    The University of British Columbia – Vancouver, British Columbia, Canada

    Assistant Professor – Neuro-Oncology

    UC San Francisco – Location

    Postdoctoral Scientist – Senescence and Cancer

    Cancer Research Center of Lyon – Lyon, France

    Research Fellow – Breast Cancer Biology

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Position – Cancer Immunotherapy

    University of Notre Dame – Notre Dame, Indiana, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter